U.K., EU Bodies Warn of Drug Delays Ahead of Final Brexit Talks
- Groups ask for one-year phase-in for Northern Ireland protocol
- Covid threatens more disruption across pharma industry
Bags of completed medical prescriptions at a pharmacy in Longfield, Kent.
Photographer: Simon Dawson/BloombergThis article is for subscribers only.
Sign up to our Brexit Bulletin, follow us @Brexit and subscribe to our podcast.
U.K. and European Union pharmaceutical groups called on politicians to prioritize medicines in last-ditch Brexit trade talks this week, as the industry grapples with political and regulatory uncertainty and pressure from the pandemic.